Dr. Scott Rocklage is a Proficient Scientist and Corporate Leader

Dr. Scott Rocklage currently holds the senior partner post at 5 AM Venture Management. He majored in chemistry in both his undergraduate and postgraduate studies. Dr. Rocklage is a graduate of the University of California Berkeley. He is also a Ph.D. He obtained his doctorate from MIT. Dr. Rocklage conducted his studies at Professor Richard R. Schrock laboratory, a Nobel Prize Winner in the field of chemistry. He is married to Patty Rocklage.

 

Dr. Rocklage’s work history

 

Dr. Rocklage commenced his career in 1990 at Nycomed Interventional. He was Nycomed’s CEO in charge of operational activities. After two years, he was rose to the chair of the firm. In 1994, he helped establish Cubist Pharmaceuticals Inc. and worked as its chief executive officer for almost a decade. Michael Bonney succeeded him in 2003. Dr. Rocklage began working at 5 AM Ventures in 2003. A few years later, he ascended to the managing partner position. Throughout his career, Dr. Rocklage has held various executive positions in many healthcare companies.

 

Before joining 5 AM Ventures, he was the head of EPIRUS Biopharmaceuticals for three months. He also worked as the President of Amersham Health Centre, a hospital based in England. Dr. Rocklage also served as the chairman of Ilypsa, Inc. Dr. Rocklage has served on several boards of companies like Cidara Therapeutics Inc., Semprus Bioscience Corporation, and Kinestral Inc., and Whitehead Institute. He also worked as the director of Pulmatrix, MDS Proteomics, Achaogen, Inc. He has managed companies like VBI Vaccines, Protana Inc., and Miikana Therapeutics Inc.

 

Dr. Rocklage’s achievements

 

For years, Dr. Scott Rocklage has gained extensive experience in the healthcare management sector. His stellar record and extensive scientific knowledge speak for itself. Dr. Rocklage has published over 100 peer-reviewed publications. He has facilitated the licensing of approximately 30 U.S. patents. He has also facilitated the approval of various drugs by the FDA. These drugs include Cubicin®, Teslascan®, and Omniscan™. Dr. Rocklage partially financed the construction and renovation of nanotechnology and nanochemistry laboratory at the MIT. Dr. Rocklage made his contribution by giving out a donation of $250,000 to assist with the construction costs.